Metastatic solid tumors may be curable now. Among the most profound results presented over the weekend at the European Society for Medical Oncology (ESMO) 2024 Congress were the 10-year data from the Checkmate-067 and Keynote-006 trials, the phase III trials that tested Opdivo (nivolumab, Bristol Myers Squibb Co.) and Keytruda (pembrolizumab, Merck & Co. Inc.) as first-line agents in advanced or metastatic melanoma. Read More
The University of Michigan has published details on the discovery and preclinical characterization of a new potent and selective proteolysis targeting chimera (PROTAC) degrader of BRD9, CW-3308. Synthesis and optimization of two different cereblon ligands led to the discovery of a novel series of highly potent BRD9 degraders, with CW-3308 selected as the lead candidate. Read More
Voyager Therapeutics Inc. has announced the selection of a development candidate in a gene therapy program for the treatment of an undisclosed neurological disease under its collaboration with Neurocrine Biosciences Inc. Read More
UL16 binding protein 6 (ULBP6) is a molecule belonging to the stress-induced NKG2D ligand family and its expression is up-regulated on the surface of cancerous cells, binding to the immune-activating NKG2D receptor on natural killer (NK) and T cells, thus promoting immune evasion. Read More
To date, there have not been any reported robust small-animal models of human parainfluenza virus type 3 (HPIV-3) infection. Researchers from Katholieke Universiteit Leuven and affiliated organizations thus developed a novel inbred mouse HPIV-3 infection model for prophylactic and therapeutic modalities. Read More
Cullinan Therapeutics Inc. has submitted an IND application to the FDA to evaluate its CD19 x CD3 bispecific T-cell engager, CLN-978, for the treatment of systemic lupus erythematosus (SLE). Read More
Shenzhen Genuine Biotech Co. Ltd. has disclosed tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) allosteric inhibitors reported to be useful for the treatment of cancer. Read More
OS Therapies Inc. has announced the development and in vitro concept data for two novel tunable antibody-drug conjugate (tADC) therapeutic candidates leveraging the company’s proprietary Silinker technology. Read More
Omass Therapeutics Ltd. has identified compounds acting as melanocortin MC2 receptor antagonists reported to be useful for the treatment of congenital adrenal hyperplasia, Cushing syndrome, depression, ectopic ACTH syndrome, polycystic ovary syndrome and septic shock. Read More
The National Institutes of Health (NIH) has established a pandemic preparedness research network to conduct research on high-priority pathogens most likely to threaten human health with the goal of developing effective vaccines and monoclonal antibodies. Read More
Shenzhen Zhongge Biotechnology Co. Ltd. has divulged stimulator of interferon genes protein (STING; TMEM173) agonists reported to be useful for the treatment of cancer, Alzheimer’s disease, pulmonary fibrosis, heart failure, infections, psoriasis, Sjögren’s syndrome and systemic lupus erythematosus, among others. Read More
Osteogenesis imperfecta (OI) is characterized by low bone mass, with increased risk of bone fracture due to mutations in certain genes encoding type I collagen, such as COL1A1 and COL1A2. Read More
